Alpha-1 MP
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha1-Antitrypsin Deficiency
Conditions
Alpha1-Antitrypsin Deficiency
Trial Timeline
Jul 29, 2016 → Mar 15, 2017
NCT ID
NCT02870309About Alpha-1 MP
Alpha-1 MP is a phase 1/2 stage product being developed by Grifols for Alpha1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02870309. Target conditions include Alpha1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02870348 | Phase 1/2 | Completed |
| NCT02870309 | Phase 1/2 | Completed |
| NCT02796937 | Phase 3 | Recruiting |
| NCT01983241 | Phase 3 | Active |
Competing Products
3 competing products in Alpha1-Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-864 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) | Grifols | Phase 1/2 | 38 |
| Alpha-1 MP | Grifols | Phase 1/2 | 38 |